Seegene to unveil breakthrough technology for highly multiplexed quantitative real-time molecular assays at AACC 2012

Quantitative TOCE™(qTOCE™)technology to expedite the development of novel MDx tests

?

Gaithersburg[ct1]?,Maryland and Seoul, Korea, July 12, 2012? Seegene Inc., (096530.KQ)announced today that it will disclose highly multiplexed quantitative real-time technology at the 2012 American Association of Clinical Chemistry (AACC) annual meeting, held in Los Angeles, from July 17-19.

Real-time PCR is currently considered the gold standard for clinical molecular diagnostics because of its versatility, speed and ease of use. ?However, few advancesin the real-time PCR chemistry havebeen made over the last 20 years, despite a growing demand for tests that both deliver high multiplexing and quantification of pathogen targets. The performance of today’s multiplex qPCR technology is limited by conventional real-time thermal cyclers “one channel, onetarget” testing capability, whichis a major obstacle to achieving high multiplex analysis in qPCR.

To overcome this limitation, Seegene has developed quantitative TOCE (“qTOCE”) Technology, an artificial template system that delivers signal generation and multiple melting temperature analysis.qTOCE successfully turns ?conventional four-color qPCR platforms into a powerful system for simultaneous detection and quantification of multiple targets in a single channel (“one channel, many targets”). ?qTOCE can expand the detection and quantitative capabilities of these qPCR systems to as many as 28 different targets from a single sample, in a single reaction. The capabilities of qTOCE will enable multiplex assay development across a wide range of applications, including high-multiplex quantitative real-time PCR and highly selective mutational analysis, and be a powerful new tool for molecular assay development in real time.

“qTOCE is a breakthrough technology enabling a dynamic new approach to the design and development of molecular based assays,” said Dr. Jong-Yoon Chun, founder, CTO and CEO of Seegene.“qTOCE will help remove the many technical barriers to the development of new assays, empowering systematic screening as well as syndrome-based diagnosis.?qTOCE will enable scientists to vastly expand testing parameters and create a new horizon for diagnostics with high clinical utility.”

Validating the effectiveness and utility of qTOCE, Seegene is introducing several new molecular testsbased on the new technology:

QuantPlex™?RV-16 Assay:The first real time molecular assay that detects and quantifies of?21respiratory viral pathogens associated with respiratory disease.

QuantPlex™?HPV28?Genotyping?Assay:?The first real time molecular assay for the detection,?genotyping?and quantification of19high-risk and 9low-risk genotypes of the Human Papilloma virus (HPV).

Quantplex™ MTB/MDR/XDR Detection Assay:The first real time molecular assay that detects Mycobacterium tuberculosis and resistance mutations associated with multiple drug resistant (MDR) and extensively drug resistant (XDR) forms of M. tuberculosis.

Quantplex™ STI-7 Assay:The first real time molecular assay that detectsand quantifies 7 sexually transmitted infections in real-time.

Dr. Chun added “Due to the many powerful benefits and implications that qTOCE offers, we want to make the technology widely available in the marketplace and to the patient. We believe that qTOCE hasthe potential to invigorate the businesses of traditional diagnostic companies, and ‘wake up’ a large portion of the market to new opportunities in molecular diagnostics.”

To set up a meeting with Seegene and learn more about qTOCE send an email to idealway@seegene.com.

?

Or visit Seegene Booth#523 at AACC in Los Angeles July 17? 19^th, 2012.

?

?

About Seegene

Seegene is the world’s leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene’s core enabling technologies ? ACP™, DPO™, READ, andqTOCE™ - are the foundation for M-MoDx tests that can simultaneously detect, differentiate and quantitate multiple targets with high sensitivity, specificity and reproducibility.? Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.

?

For more information please visit www.seegene.com? or call +301-762-9066.